Opinion|Videos|January 10, 2025

Assessing New Therapies for Retinal Diseases

Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.

Video content above is prompted by the following:

  • New Therapies:
  • Aflibercept 8 mg

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.


Latest CME